635299-81-9

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 171192-72-6 (2R,4R)-ethyl N¹-benzyl-4-hydroxypyrrolidine-2-carboxylate 
• 114676-59-4 (2R,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride 
• 2584-71-6 cis-hydroxy-D-proline 
• 114676-53-8 (2R,4R)-methyl 1-benzyl-4-hydroxypyrrolidine-2-carboxylate 
• 1271809-99-4 methyl (2R,4R)-1-benzyl-4-[tert-butyl(dimethyl)silyl]oxy-pyrrolidine-2-carboxylate 
• 114676-47-0 (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid methyl ester 
• 51-35-4 4R-4-hydroxyproline 

Downstream Products

• 825644-18-6 (3S,5R)-1-benzyl-5-((tert-butyldimethylsilyl)oxy)piperidin-3-ol 
• 1271810-11-7 (3R,5S)-tert-butyl 3-azido-5-fluoropiperidine-1-carboxylate 
• 1271810-13-9 tert-butyl (3R,5S)-3-amino-5-fluoro-piperidine-1-carboxylate 
• 1271810-19-5 (3'R,5'S)-tert-butyl 3-(3-chloro-5-fluorophenylamino)-5'-fluoro-2-oxo-1,3'-bipiperidine-1'-carboxylate 
• 1271806-79-1 (3'R,5'S)-1'-(6-amino-5-fiuoropyrimidin-4-yl)-3-(3-chloro-5-fluorophenylamino)-5'-fluoro-1,3'-bipiperidin-2-one 
• 1271810-43-5 (3R,5S)-tert-butyl 3-azido-5-(benzoyloxy)piperidine-1-carboxylate 
• 1562988-38-8 (S)-5-amino-3,3-difluoro-piperidine-1-carboxylic acid benzyl ester 
• 708253-90-1 [(3R,5S)-5-azido-1-benzyl-3-piperidyl]oxy-tert-butyl-dimethylsilane 
• 708253-91-2 tert-butyl N-[(3S,5R)-1-benzyl-5-[tert-butyl(dimethyl)silyl]oxy-3-piperidyl]carbamate 
• 1187055-35-1 benzyl (3S,5R)-3-(tert-butoxycarbonylamino)-5-[tert-butyl(dimethyl)silyl]oxy-piperidine-1-carboxylate 
• 1187055-40-8 benzyl (3S)-3-(tert-butoxycarbonylamino)-5-oxo-piperidine-1-carboxylate 
• 1187055-41-9 benzyl (5S)-5-(tert-butoxycarbonylamino)-3,3-difluoropiperidine-1-carboxylate 
• 1611481-19-6 tert-butyl ((3S,5R)-1-benzyl-5-hydroxypiperidin-3-yl)carbamate 

Relevant academic research and scientific papers

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

BRUTON'S TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Enantiospecific synthesis and receptor binding of novel dopamine receptor ligands employing natural 4-hydroxyproline as a practical and flexible building block

Starting from natural 4-hydroxyproline, an ex-chiral pool approach is described giving access to 2-aminoalkylpyrrolidine derivatives that were used as chiral building blocks for the synthesis of bioactive 2-methoxybenzamide derivatives. The 4-hydroxy substituent can be displaced employing organocuprates as useful carbanion equivalents. Dopamine and serotonin binding studies involving the subtypes D1, D2long, D2short, D3 and D4 as well as 5-HT1A and 5-HT2, respectively, provided interesting insights into stereoselective structure activity relationships. The (2S,4R)-2-aminomethylpyrrolidine derivative ent-66 and the (2R,4S)-2- aminoethylpyrrolidine derivative 68 showed remarkable affinity and preference for the dopamine D3 and D4 receptor subtypes, respectively, both being putatively associated to the symptoms of schizophrenia.